



# ADVANCES IN DIVERSE MEDICAL FIELDS

GABAPENTIN AND
NORTRIPTYLINE EXPLORING
NEUROPATHIC PAIN
MANAGEMENT



# **CLINICAL TRIALS FRONTIER**












# **Other Indications**

MOLECULE	INDICATION	Phase	No. of Sites	No. of Patients
Remogliflozin Etabonate, Metformin and Vildagliptin	Type 2 Diabetes Mellitus	IV	7	215
Gabapentin and Nortriptyline	Neuropathic pain	IV	6	350
Linagliptin & Dapagliflozin	Type 2 Diabetes Mellitus	III	6	232
SARS-CoV-2 Equine Antiserum Ig	COVID -19	I	2	72
BIAPENEM	UTI, Pnuemonia, Complicated Intra Abdominal Infections	III	19	180
Sildenafil and Avanafil	Erectile Dysfunction	III	8	220
Ferric Carboxymaltose Injection	Iron deficiency Anemia	BE	12	180
Filgotinib	Active Ulcerative Colitis	III	46	150

# SARS-CoV-2 Equine Antiserum Ig - Investigating Treatment for COVID-19

### Other Indications



Other Indications No. of Sites

■ Other Indications No. of Patients

## **Conclusion**

The ongoing clinical trials in diverse medical fields exemplify the breadth of ongoing research aimed at addressing a variety of health conditions. From diabetes management and neuropathic pain to COVID-19 treatment, infections, erectile dysfunction, and anemia, these trials represent a commitment to advancing medical care across multiple indications. The outcomes of these trials have the potential to significantly impact patient care, offering new and improved treatment options across a spectrum of health concerns.